{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:21:34Z","timestamp":1767903694493,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Santen Pharmaceutical Co., Ltd., Osaka, Japan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12325-018-0718-9","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T11:52:54Z","timestamp":1528199574000},"page":"796-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Multicenter, Randomized, Controlled Study Comparing Tafluprost\/Timolol Fixed Combination with Latanoprost\/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension"],"prefix":"10.1007","volume":"35","author":[{"name":"On behalf of the Tafluprost\/Timolol Versus Latanoprost\/Timolol (TTVLT) Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Hizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayo","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"key":"718_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137.","journal-title":"Br J Ophthalmol"},{"key":"718_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002512-200522010-00001","volume":"22","author":"RE Marquis","year":"2005","unstructured":"Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005;22:1\u201321.","journal-title":"Drugs Aging"},{"key":"718_CR3","unstructured":"National Institute for Health and Care Excellence. Glaucoma: diagnosis and management, NICE guideline [NG81] 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/ng81\n                    \n                  ."},{"key":"718_CR4","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","volume":"122","author":"PA Newman-Casey","year":"2015","unstructured":"Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308\u201316.","journal-title":"Ophthalmology"},{"key":"718_CR5","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"718_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/00061198-200310000-00001","volume":"12","author":"JC Tsai","year":"2003","unstructured":"Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12:393\u20138.","journal-title":"J Glaucoma"},{"key":"718_CR7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","volume":"15","author":"G Hollo","year":"2014","unstructured":"Hollo G, Topouzis F, Fechtner RD. Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice. Exp Opin Pharmacother. 2014;15:1737\u201347.","journal-title":"Exp Opin Pharmacother"},{"key":"718_CR8","first-page":"129","volume":"101","author":"European Glaucoma Society","year":"2017","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma, 4th edition\u2014Chapter 3. Br J Ophthalmol. 2017;101:129\u201391.","journal-title":"Br J Ophthalmol"},{"key":"718_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.6061\/clinics\/2013(10)05","volume":"68","author":"HH Russ","year":"2013","unstructured":"Russ HH, Nogueira-Filho PA, Barros Jde N, et al. Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial. Clinics (Sao Paulo). 2013;68:1318\u201324.","journal-title":"Clinics (Sao Paulo)"},{"key":"718_CR10","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1167\/iovs.13-11942","volume":"54","author":"T Shoji","year":"2013","unstructured":"Shoji T, Sato H, Mizukawa A, et al. Hypotensive effect of latanoprost\/timolol versus travoprost\/timolol fixed combinations in NTG patients: a randomized, multicenter, crossover clinical trial. Invest Ophthalmol Vis Sci. 2013;54:6242\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"718_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/112067210701700206","volume":"17","author":"F Topouzis","year":"2007","unstructured":"Topouzis F, Melamed S, Danesh-Meyer H, et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%\/timolol 0.5% to once-daily latanoprost 0.005%\/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:183\u201390.","journal-title":"Eur J Ophthalmol"},{"key":"718_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/jop.2014.0104","volume":"31","author":"T Kanamoto","year":"2015","unstructured":"Kanamoto T, Kiuchi Y, Tanito M, et al. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface. J Ocul Pharmacol Ther. 2015;31:156\u201364.","journal-title":"J Ocul Pharmacol Ther"},{"key":"718_CR13","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/bjo.79.11.1007","volume":"79","author":"S Shimmura","year":"1995","unstructured":"Shimmura S, Ono M, Shinozaki K, et al. Sodium hyaluronate eyedrops in the treatment of dry eyes. Br J Ophthalmol. 1995;79:1007\u201311.","journal-title":"Br J Ophthalmol"},{"key":"718_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","volume":"123","author":"T Li","year":"2016","unstructured":"Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. Ophthalmology. 2016;123:129\u201340.","journal-title":"Ophthalmology"},{"key":"718_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/OPTH.S6368","volume":"4","author":"M Aihara","year":"2010","unstructured":"Aihara M. Clinical appraisal of tafluprost in the reduction of evaluated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. Clin Ophthalmol. 2010;4:163\u201370.","journal-title":"Clin Ophthalmol"},{"key":"718_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s12325-014-0151-7","volume":"31","author":"G Hollo","year":"2014","unstructured":"Hollo G, Vuorinen J, Tuominen J, Huttunen T, Ropo A, Pfeiffer N. Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products. Adv Ther. 2014;31:932\u201344.","journal-title":"Adv Ther"},{"key":"718_CR17","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1185\/03007995.2015.1039504","volume":"31","author":"H Lou","year":"2015","unstructured":"Lou H, Wang H, Zong Y, Cheng JW, Wei RL. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res. 2015;31:1139\u201347.","journal-title":"Curr Med Res"},{"key":"718_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s12325-014-0125-9","volume":"31","author":"AG Konstas","year":"2014","unstructured":"Konstas AG, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost, timolol BAK-free versus latanoprost, timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther. 2014;31:592\u2013603.","journal-title":"Adv Ther"},{"key":"718_CR19","doi-asserted-by":"publisher","first-page":"e0158797","DOI":"10.1371\/journal.pone.0158797","volume":"11","author":"M Fuwa","year":"2016","unstructured":"Fuwa M, Ueda K, Akaishi T, et al. Advantages of efficacy and safety of fixed-dose tafluprost\/timolol combination over fixed-dose latanoprost\/timolol combination. PLoS One. 2016;11:e0158797.","journal-title":"PLoS One"},{"key":"718_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Bringnole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"718_CR21","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1097\/IJG.0000000000000265","volume":"25","author":"M Aihara","year":"2016","unstructured":"Aihara M, Ikeda Y, Mizoue S, Arakaki Y, Kita N, Kobayashi S. Effect of switching to travoprost preserved with SofZia in glaucoma patients with chronic superficial punctate keratitis while receiving BAK-preserved latanoprost. J Glaucoma. 2016;25:e610\u20134.","journal-title":"J Glaucoma"},{"key":"718_CR22","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/j.1755-3768.2012.02565.x","volume":"91","author":"M Aihara","year":"2013","unstructured":"Aihara M, Oshima H, Araie M. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface\u2014a multicentre randomized single-masked study. Acta Ophthalmol. 2013;91:e7\u201314.","journal-title":"Acta Ophthalmol"},{"key":"718_CR23","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1097\/IJG.0000000000000020","volume":"24","author":"K Suzuki","year":"2015","unstructured":"Suzuki K, Teranishi S, Sagara T, et al. Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis. J Glaucoma. 2015;24:e145\u201350.","journal-title":"J Glaucoma"},{"key":"718_CR24","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1111\/aos.13401","volume":"95","author":"M Aihara","year":"2017","unstructured":"Aihara M, Adachi M, Matsuo H, et al. Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin-treated glaucoma patients. Acta Ophthalmol. 2017;95:e720\u20136.","journal-title":"Acta Ophthalmol"},{"key":"718_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/OLQ.0b013e3181644669","volume":"35","author":"E Adriaens","year":"2008","unstructured":"Adriaens E, Remon JP. Mucosal irritation potential of personal lubricants relates to product osmolality as detected by the slug mucosal irritation assay. Sex Transm Dis. 2008;35:512\u20136.","journal-title":"Sex Transm Dis"},{"key":"718_CR26","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.ophtha.2009.06.024","volume":"116","author":"JC Tsai","year":"2009","unstructured":"Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30\u20136.","journal-title":"Ophthalmology"},{"key":"718_CR27","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S0161-6420(02)01974-7","volume":"110","author":"PP Chen","year":"2003","unstructured":"Chen PP. Blindness in patients with treated open-angle glaucoma. Ophthalmology. 2003;110:726\u201333.","journal-title":"Ophthalmology"},{"key":"718_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00044011-200424060-00004","volume":"24","author":"P Denis","year":"2004","unstructured":"Denis P, Lafuma A, Berdeaux G. Medical outcomes of glaucoma therapy from a nationwide representative survey. Clin Drug Investig. 2004;24:343\u201352.","journal-title":"Clin Drug Investig"},{"key":"718_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/IJG.0b013e318033500f","volume":"16","author":"E Forsman","year":"2007","unstructured":"Forsman E, Kivela T, Vesti E. Lifetime visual disability in open-angle glaucoma and ocular hypertension. J Glaucoma. 2007;16:313\u20139.","journal-title":"J Glaucoma"}],"updated-by":[{"DOI":"10.1007\/s12325-018-0864-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-018-0718-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0718-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-018-0718-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T19:07:37Z","timestamp":1559675257000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-018-0718-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["718"],"URL":"https:\/\/doi.org\/10.1007\/s12325-018-0718-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12325-018-0864-0","asserted-by":"object"}]},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"3 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original publication, the range to derive the P values is incorrectly represented in Table\u00a02 and Table\u00a03. The corrected tables are provided below.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}